This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Luminex Boosts Product Portfolio With New xMAP Technology
by Zacks Equity Research
Luminex (LMNX) commences rollout of new xMAP INTELLIFLEX Systems, which will expand its xMAP Technology.
3 Cheap MedTech Stocks Set to Gain Once Coronavirus Crisis Ebbs
by Sriparna Ghosal
Once the pandemic-led crisis eases, these MedTech stocks will likely flourish on the back of number of positive developments.
IDEXX Gains on Diagnostics Revenues, New Coronavirus Tests
by Zacks Equity Research
IDEXX's (IDXX) human health business, OPTI Medical Systems' newly-developed PCR laboratory test kit named OPTI SARS-CoV-2 RNA RT-PCR gains market acceptance.
Boston Scientific's (BSX) ICM System Receives FDA Approval
by Zacks Equity Research
Boston Scientific's (BSX) new ICM System gets the FDA's nod, thus paving way for better detection and treatment of arrhythmias.
Here's Why You Should Retain DaVita in Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA), thanks to solid prospects.
Myriad Genetics Unveils New Home DNA Sample Collection Kit
by Zacks Equity Research
Myriad Genetics' (MYGN) home DNA sample collection test kit for its GeneSight Psychotropic test enables physicians to remotely provide treatment options to patients with mental health issues.
4 Cheap MedTech Stocks Poised to Beat Industry Post-Pandemic
by Debanjana Dey
Here are some MedTech stocks which might be a solid investment option post the coronavirus blues.
NextGen Virtual Visits Offers Remote Eye Care Facilities
by Zacks Equity Research
The offering will expand NextGen's (NXGN) ophthalmology services during the coronavirus crisis.
Masimo's New Solution to Reduce Opioid Withdrawal Symptoms
by Zacks Equity Research
Masimo's (MASI) new solution can help reduce symptoms associated with opioid withdrawal, thereby helping OUD patients with their treatment.
LabCorp's Xcellerate Coronavirus Solution to Aid Clinical R&D
by Zacks Equity Research
This solution by LabCorp (LH) takes the idea from Covance's COVID-19 Operational Recovery Team to better understand the necessities.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Allscripts (MDRX) continues to benefit from lucrative deals and strong prospects in Sunrise EHR. However, margin contraction remains a woe.
Luminex Expands COVID-19 Testing With New Antibody Test
by Zacks Equity Research
Luminex (LMNX) submits an EUA request to the FDA for its first multi-antigen IgG assay.
LHC Group Inks Deal With Orlando Health to Improve HCBS
by Zacks Equity Research
This deal is expected to boost LHC Group's (LHCG) home and community-based business segment.
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D. However, forex remains a woe.
Masimo's (MASI) New Offering to Improve Patient Outcomes
by Zacks Equity Research
Masimo's (MASI) Centroid gets FDA clearance and can help clinicians monitor patient position, thereby improving patient outcomes.
Ecolab's Unit Unveils Test Kit for Cooling Water Management
by Zacks Equity Research
Ecolab's (ECL) bacteria test kit drastically simplifies water-chemistry testing and compliance for cooling water health.
LabCorp Neutralizing Antibody Test to Aid Coronavirus Vaccine R&D
by Zacks Equity Research
The information related to neutralizing antibody test of LabCorp (LH) can also be used for the screening of convalescent plasma for prophylactic and therapeutic use.
STAAR Surgical (STAA) Jumps: Stock Rises 8.9%
by Zacks Equity Research
STAAR Surgical (STAA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Ecolab's New Pest Elimination Service to Ensure Food Safety
by Zacks Equity Research
Ecolab's (ECL) introduces Rodent Ceiling Service, which can help reduce the risk to food safety and public health.
Here's Why You Should Add Surmodics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Surmodics (SRDX), thanks to solid prospects.
NextGen Virtual Visits Supports Women Health During COVID-19
by Zacks Equity Research
Capital Women's Care is set to expand NextGen's (NXGN) women's healthcare services during the coronavirus emergency.
Masimo (MASI) Boosts Product Portfolio with New Solution
by Zacks Equity Research
Masimo (MASI) unveils Masimo Sleep to help consumers better understand their quality of sleep.
What's in Store for Patterson Companies' (PDCO) Q4 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect solid performance at Dental segment.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) continues to gain from solid prospects in EHR and strategic deals. However, intense competition remains a woe.
Allscripts' (MDRX) Veradigm Partners with PAN Foundation
by Zacks Equity Research
This partnership between Allscripts (MDRX) and PAN Foundation is expected to boost patient outcomes.